Single-dose topiramate in migraine prophylaxis

Comparison of the therapeutic effects of using single-dose and twice-daily topiramate for migraine prophylaxis in children aged 5 to 18 years referred to Tehran Children's Medical Center Hospital

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20250508065645N1

Enrollment

Registered

2025-05-16

Start date

2025-06-22

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine. Migraine

Interventions

Intervention group: In the present study the calculated therapeutic dose of topiramate for pediatric patients was based on guidelines from the American Academy of Neurology (AAN) and the American Head

Eligibility

Sex/Gender

All

Age

5 Years to 18 Years

Inclusion criteria

Inclusion criteria: The inclusion criteria for the study are children aged 5 to 18 years diagnosed with migraine according to the International Classification of Headache Disorders, 3rd edition (ICHD-3) , candidates for prophylactic treatment who experienced a minimum of two migraine attacks per month , and obtained informed consent from their parents or legal guardians to participate in the study

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Headache frequency, headache severity, headache duration, headache-related disability, side effects. Timepoint: At the beginning of the study, 3 months and 6 months after taking the medication. Method of measurement: History, Verbal Pain Scale, Visual Analogue Scale, Pediatric Migraine Disability Assessment (PedMIDAS).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSina Fathi

Tehran University of Medical Sciences

sina_fth74@yahoo.com+98 21 2238 1781

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026